Sign in
ABP Stock Price, Chart, Stats & News
Abpro Corporation
Save
Abpro Corporation (ABP) does not currently pay a dividend.
1.06M
Market cap
–
Current P/E
–
Forward P/E
ABP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -55.19% |
Operating margin | -7950.82% |
Pretax margin | -7702.19% |
Net margin | -7670.49% |
Effective tax rate | 0.41% |
ROA | -824.25% |
ROE | 83.19% |
D/E | -0.01x |
Interest coverage ratio | -12.28x |
ABP valuation
P/E | – |
P/S | 5.78x |
P/B | -0.08x |
P/CF | -0.10x |
P/FCF | -0.08x |
P/OCF | -0.10x |
PEG | -0.05x |
EV multiple | -0.10x |
About
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye.
Similar securities
Based on sector and market capitalization
Report issue